Cellvizio® by Mauna Kea Technologies

Cellvizio® is the real-time in vivo cellular imaging platform that revolutionizes the way physicians diagnose and treat patients.

[Cellvizio® by Mauna Kea Technologies @maunakeatech]

.@ESGE_news recommends #Cellvizio for enhancing pancreatic cyst diagnosis, advancing its commercial adoption. A major step towards improving diagnostic accuracy and reducing unnecessary surgeries for patients worldwide!

https://t.co/QEffALABhT

#GITwitter #PancreaticCysts

[Cellvizio® by Mauna Kea Technologies @maunakeatech]

MKT H1 2026 Highlights: accelerating global growth!
- Total Sales: €3.2M (+44% CER)
- CellTolerance: €0.9M (+145%), EMEA & ROW: +261%
- With a strong H2 pipeline, we remain firmly on track toward profitability by year-end 2027. 

https://t.co/PXMAOIjLEE

$ALMKT #Cellvizio

[Cellvizio® by Mauna Kea Technologies @maunakeatech]

“It's a whole spectrum of cases that I use Cellvizio for.”

Dr. Ravi Prakash uses #Cellvizio at every stage of Barrett's Esophagus management.

Here's how: https://t.co/3OmlhPhzMT

#BarrettsEsophagus

[Cellvizio® by Mauna Kea Technologies @maunakeatech]

“When [patients] come to you, the expectation is that they can actually get most of the information in one or two settings and providing this value for the patient with real-time histological assessment is deeply impactful.” -Dr. Ravi Prakash

https://t.co/XQhnaGMMNm

#GITwitter

[Cellvizio® by Mauna Kea Technologies @maunakeatech]

This study underscores #Cellvizio's transformative role in #IBD mgmt, offering real-time cellular insights for assessing inflammation, healing, relapse prediction, & therapy guidance, shaping the future of targeted IBD care.

https://t.co/oh9wOX39jY
#GITwitter
@CrohnsColitisFn

[Cellvizio® by Mauna Kea Technologies @maunakeatech]

"You want to make sure you're ablating the right area, especially when you're close to achieving CRIM around the GE junction. #Cellvizio is very helpful in assessment of all these areas.”
-Dr. Ravi Prakash

Catch the full conversation: https://t.co/e8z1aPhi6r

#BarrettsEsophagus

[Cellvizio® by Mauna Kea Technologies @maunakeatech]

“#Cellvizio is crucial in giving me this real-time assessment of what the tissue is, whether I proceed with ablation treatment or whether I proceed with resection.”

-Dr. Ravi Prakash

Watch the full insights: https://t.co/fkPdb5b7zq

#BarrettsEsophagus

[Cellvizio® by Mauna Kea Technologies @maunakeatech]

I think people underestimate the utilization of #Cellvizio in the ablation space.”

-Dr. Ravi Prakash

Watch the full interview here: https://t.co/kLy670AxCF

#BarrettsEsophagus #GITwitter

[Cellvizio® by Mauna Kea Technologies @maunakeatech]

Thank you to all who joined our @CellTolerance workshop in Bamberg! We showcased how #CellTolerance Test, powered by #Cellvizio, delivers real-time insights into intestinal barrier function, advancing precise, evidence-based care for #foodintolerance and #GI patients. #GITwitter

[Cellvizio® by Mauna Kea Technologies @maunakeatech]

We are pleased to announce the completion of the first @CellTolerance case in New York! Congrats to the @ss_gastro team on this milestone. We value partnering with forward-thinking clinicians to help patients with unresolved, food-related digestive symptoms.

#GITwitter

[Cellvizio® by Mauna Kea Technologies @maunakeatech]

#Cellvizio + AI enables more precise pancreatic cyst decision-making, outperforming human expert assessment for IPMN stratification.

Read: https://t.co/2Cxz0ZgLoW

@som_krishna

#PancreaticCysts  #GITwitter

[Cellvizio® by Mauna Kea Technologies @maunakeatech]

A groundbreaking preclinical study in @Pharmaceut_MDPI demonstrates the potential of #Cellvizio for the intraoperative visualization of #prostatecancer at a cellular resolution.
https://t.co/o25haTdnro

#GITwitter

[Cellvizio® by Mauna Kea Technologies @maunakeatech]

Happy National Cancer @SurvivorsDay! To every survivor,  your strength inspires the entire healthcare community. We're proud to support the physicians and teams that make more survival stories possible. #NCSD2026 #EarlyDetection #SeeCellsChangeLives

[Cellvizio® by Mauna Kea Technologies @maunakeatech]

An enriching #pancreaticcyst nCLE with #Cellvizio Workshop at @Hopital_Mermoz! Experts from France, Spain, & Serbia united to share the latest evidence & techniques to effectively risk-stratify pancreatic cysts, making a profound difference for patients.

#GITwitter

[Cellvizio® by Mauna Kea Technologies @maunakeatech]

A new @UEGJournal study shows the impact of triple healing for #IBD: histological remission & an intact intestinal barrier in both the ileum and colon.
Triple healing: 0 relapses in 29 patients over 24 months.
Fall short of it: ~33% relapse.
https://t.co/2NfgC3O2jK

#GITwitter

[Cellvizio® by Mauna Kea Technologies @maunakeatech]

The @WorldGastroOrg established #WDHD2026 to raise awareness about digestive health issues & promote preventative measures. As a global medical device company, we’re dedicated to providing solutions to take charge of gut health.

https://t.co/vvi4K9HXjr
#GITwitter

[Cellvizio® by Mauna Kea Technologies @maunakeatech]

#ICYMI @CellTolerance is officially expanding into the United Arab Emirates & Turkey! With #IBS & food intolerances impacting up to 27% of the population in these markets, our precision diagnostics are ready to make a major impact.
https://t.co/sN6iXVI3d3

#Cellvizio $ALMKT

[Cellvizio® by Mauna Kea Technologies @maunakeatech]

@MaunaKeaTech has secured regulatory clearances for #Cellvizio in the UAE & Turkey and the first @CellTolerance commercial installation in a region where #IBS & #FoodIntolerances affect up to 27% of the population.
Read the full PR:
https://t.co/bZ55pBA7GF
$ALMKT #GITwitter

[Cellvizio® by Mauna Kea Technologies @maunakeatech]

#WorldIBDDay raises awareness for Crohn’s Disease & Ulcerative Colitis, two chronic inflammatory bowel diseases (#IBD) affecting millions worldwide. To learn how #Cellvizio can be superior to conventional severity scoring, visit: https://t.co/6UkNKmjnF7

@CrohnsColitisFn

[Cellvizio® by Mauna Kea Technologies @maunakeatech]

The stakes for early detection have never been higher. The road to Complete Remission of Intestinal Metaplasia (CRIM) is long. We can't control the rise of the disease alone, but with #Cellvizio, we can control how we find and treat it.

https://t.co/XM2r7WQWxw

#GITwitter